VKTX Viking Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why VKTX matters now
Viking Therapeutics, Inc. (VKTX) is a US stock in Healthcare. The latest InvestLog snapshot shows $38.86 with -5.54% on the session and $4.51B in market capitalization; recent performance reads 1-month +6.97% and YTD -13.64%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-158.3M, and EPS of $-1.37. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -9.6%.
The latest indexable market news headline is "Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $95.00; recent insider activity includes Chen Hubert C filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
7.00
P/S
0.00
EV/EBITDA
-7.22
DCF Value
$1.03
FCF Yield
-9.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-71.3%
ROA
-77.7%
ROIC
-100.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-158.3M | $-1.37 |
| Q4 2025 | $0.00 | $-157.7M | $-1.38 |
| FY 2025 | $0.00 | $-359.6M | $-3.19 |
| Q3 2025 | $0.00 | $-90.8M | $-0.81 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$93.60
Target (Median)
$95.00
Target Range
$83.00 - $101.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.68
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.